drugset / Trial / NCT00878293
Painful Diabetic Polyneuropathy Trial With a New Centrally Acting Analgesic
RandomizedCrossoverTriple-blindTreatment
Summary
The purpose of this trial is to determine whether the new centrally active analgesic and MS Continus® are effective in the treatment of painful diabetic polyneuropathy.
Timeline
- Start
- 2009-04
- Primary completion
- 2010-05
- Completion
- 2010-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cebranopadol | Small molecule | 0.8 ug | Oral |
| Subject | Cebranopadol | Small molecule | 40 ug | Oral |
| Subject | Cebranopadol | Small molecule | 120 ug | Oral |
| Subject | Cebranopadol | Small molecule | 400 ug | Oral |
| Comparator | Morphine | Other / unclassified | 60 mg | — |